All Oncology News

Jennifer M. Matro, MD provides an in-depth look at clinical trials that have added to the breast cancer paradigm and how she is interpreting the findings for clinical practice.

Fill rates of data elements on electronic health records are a major contributing factor limiting the uptake of automated services.

The addition of dalpiciclib to fulvestrant significantly prolonged progression-free survival vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to data from an interim analysis of the phase 3 DAWNA-1 trial.

Ian E. Krop, MD, PhD, has been appointed chief clinical research officer, associate cancer center director for clinical research, and director of the Yale Cancer Center Clinical Trials Office.

It is a life-changing experience to see people take the hurt, suffering, pain, and loss of cancer and transform it into a superhuman force for good and for hope.

The FDA has accepted for review a new drug application for poziotinib in patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations.

Thomas G. Martin, MD, discusses some of the exciting clinical trials open at UCSF Helen Diller Family Comprehensive Cancer Center in multiple myeloma, especially for those in the relapsed/refractory setting.

Mohammed M. Milhem, MBBS, discusses the unique elements of oncolytic vaccines in oncology and ongoing research with RP1 in melanoma and other solid tumors.

Joanne Mortimer, MD, discusses current applications for HER2-directed antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint inhibitors in early-stage and metastatic breast cancer.

Dan Vogl, MD, MSCE, discusses the unique mechanism of action of modakafusp alfa and the updated results from an expansion cohort in patients with relapsed/refractory multiple myeloma.

The novel non-viral gene therapy, EG-70, produced a complete response rate of 83% at 3 months in evaluable patients with high-grade non–muscle invasive bladder cancer with carcinoma in situ who were unresponsive to Bacillus Calmette-Guérin.

Saad Z. Usmani, MD, MBA, FACP, shares key takeaways from presentations given during the meeting on the evolving paradigms of frontline, early relapsed, and late relapsed multiple myeloma, the current role of bispecific antibodies and CAR T-cell therapy, and emerging immunotherapies and also trials in progress in the space.

Laura Finn, MD, provides a deep dive into pivotal data with combinations and novel agents that have changed the paradigm for patients with newly diagnosed, early relapsed, and late relapsed multiple myeloma.

John T. Cole, MD, discusses how updates in HER2-positive breast cancer have affected sequencing strategies, selecting between CDK4/6 inhibitors in the adjuvant and metastatic settings of hormone receptor HR–positive breast cancer, and the need for additional therapies in triple-negative breast cancer.

The combination of ibrutinib plus rituximab generated a high rate of complete response and undetectable minimal residual disease when used in the frontline treatment of patients with indolent clinical forms of mantle cell lymphoma, allowing for treatment interruption in most responders.

A team led by Lluis Morey, PhD, has received a five-year, $1.7 million grant from the National Institute of General Medical Sciences to investigate treatment resistance in estrogen receptor positive breast cancer.

Daniel G. Haller, MD, says he has relied on “cheerful serendipity” throughout his life and career.

The utilization of monoclonal antibodies such as nivolumab and Ipilimumab have become vital in shifting the treatment paradigm in gastroesophageal and gastrointestinal cancers.

Dhyan Chandra, PhD, discusses recent findings relating to low levels of cytochrome C in Black men with prostate cancer, plus plans for future research on this topic.

The long-term dramatic effects of the COVID-19 pandemic on cancer research and patient care present several challenges but also future opportunities.

The FDA’s Oncologic Drugs Advisory Committee voted against using single-country foreign data to support a biologics license application for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer.

Induction treatment with ibrutinib and rituximab was safe and active in patients with mantle cell lymphoma aged 65 years or younger, allowing for fewer cycles of subsequent chemotherapy with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone thereby reducing toxicity.

With 9 approved markers in non–small cell lung cancer and a plethora of established and emerging therapies that have been designed to target them, the need for molecular testing is more important than ever.

The organizations join forces to become one of the largest cancer research and treatment organizations in the country.

A growing recognition of the distinct clinical, pathological, and biological features of lung cancers that arise in nonsmokers is fostering greater interest in examining the molecular underpinnings of lung cancer in this patient subset.

Douglas W. Sborov, MD, MS, discusses key data and therapeutic developments that have reshaped the treatment of patients with newly diagnosed and relapsed/refractory multiple myeloma.

Jeffrey Zonder, MD, discusses his presentation at the 2021 ASH Annual Meeting on the impact of the phase 1/2 study utilizing REGN5458 in multiple myeloma.

Accelerating progress in childhood cancer faces three main obstacles: funding, drugs, and family support.

Treatment with rituximab prior to COVID-19 vaccination nearly halved the number of patients with B-cell non-Hodgkin lymphoma who developed blocking antibodies following COVID-19 vaccination compared with healthy controls.

Patients with HER2-positive, early-stage breast cancer who achieved a pathologic complete response after receiving HER2-targeted therapy experienced better outcomes in terms of disease-free survival and overall survival vs those who did not, according to data from a real-world study.